LBF20308PG01: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=<FONT FACE="Symbol">D</FONT><SUP><FONT SIZE=-1>1</FONT></SUP><SUP><FONT SIZE=-1>2</FONT></SUP>-PGJ2 has antitumor and antibiral activity, inhibiting growth of cultured L1210 cells with an IC50 of 0.7 <FONT FACE="Symbol">m</FONT>g/ml.[[Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538|{{RelationTable/GetFirstAuthor|Reference:Kato_T:Fukushima_M:Kurozumi_S:Noyori_R:,Cancer Res.,1986,46,3538}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 21:00, 6 January 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1726 |
| LipidMaps | LMFA03010020 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20308PG01 |
| Δ12-Prostaglandin J2 | |
|---|---|
| |
| Structural Information | |
| 11-oxo-15S-hydroxy-prosta-5Z,9,12E-trien-1-oic acid | |
| |
| Formula | C20H30O4 |
| Exact Mass | 334.21440944799997 |
| Average Mass | 334.4498 |
| SMILES | C(CC[C@@H](O)CC=C(C(=O)1)[C@@H](CC=CCCCC(O)=O)C=C1)CC |
| Physicochemical Information | |
| D12-PGJ2 is a decomposition product of PGD2 in the presence of albumin. Fitzpatrick_FA et al. | |
| D12-PGJ2 has antitumor and antibiral activity, inhibiting growth of cultured L1210 cells with an IC50 of 0.7 mg/ml. Kato_T et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
